Abstract
PCN80 - Cost-Effectiveness of Eml4-Alk Gene Targeted First-Line Ceritinib Treatment Among Patients With Advanced Alk-Positive Non–Small Cell Lung Cancer
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
